| P50 | author | Raymond Sanchez | Q114098204 |
| P2093 | author name string | Ronald Marcus | |
| | Taro Iwamoto | |
| | Gary Sachs | |
| | Stephen Kaplita | |
| | Linda Rollin | |
| | Robert McQuade | |
| | William Carson | |
| | Aripiprazole Study Group | |
| | Cheryl Impellizzeri | |
| | Elyse Stock | |
| | Neveen Abou-Gharbia | |
| P2860 | cites work | A rating scale for drug-induced akathisia | Q28258433 |
| | A New Depression Scale Designed to be Sensitive to Change | Q29614720 |
| | A rating scale for mania: reliability, validity and sensitivity | Q29619299 |
| | Neuroleptic-induced hyperprolactinemia | Q33586375 |
| | The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor | Q33959664 |
| | Pharmacologic agents for the treatment of acute bipolar mania. | Q34052819 |
| | A review of randomized, controlled clinical trials in acute mania | Q34106683 |
| | Consensus development conference on antipsychotic drugs and obesity and diabetes | Q34293049 |
| | Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group | Q43507067 |
| | Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 |
| | Dopamine antagonists and the development of breast cancer | Q44241349 |
| | Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling | Q44266760 |
| | Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial | Q44385585 |
| | Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials | Q44428863 |
| | Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder | Q44513113 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia | Q44649979 |
| | Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. | Q51131169 |
| | Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. | Q52900826 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| | placebo | Q269829 |
| | bipolar I disorder | Q4915474 |
| P304 | page(s) | 536-546 | |
| P577 | publication date | 2006-01-09 | |
| P1433 | published in | Journal of Psychopharmacology | Q6295819 |
| P1476 | title | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study | |
| P478 | volume | 20 | |